Please input keywords
Advancing innovative drug R&D through partnership
Biocytogen is actively seeking partnerships for Project Integrum-derived antibody assets and RenMice-based antibody discovery platforms. Biocytogen is committed to advancing novel drug R&D to benefit patients as soon as possible.
Collaboration Models
Various drug modalities
Disclosed Partners
Worldwide antibody assets or platform partners include Merck KGaA, Janssen, Xencor, ADC Therapeutics, RemeGen and BeiGene.